Gubra-Amylin NASH (GAN) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model

If you are in search of a dependable partner to assist you in evaluating the efficacy of your drug candidates for nonalcoholic fatty liver disease (NAFLD), look no further than Creative Bioarray. We stand out as the premier choice, having successfully established a robust NAFLD model induced by a Gubra Amylin NASH (GAN) diet. Our commitment to excellence is evident in our meticulous approach to model development, ensuring that it accurately reflects the human condition and thereby providing you with the most reliable data for your drug evaluation.

The Gubra Amylin NASH (GAN) diet is meticulously formulated with a specific nutrient composition and caloric density, featuring a 40% high-fat content, 22% high-fructose, and 2% high-cholesterol. This diet has gained widespread recognition and utilization for its efficacy in inducing NAFLD model in animals. By employing the GAN diet, we can effectively study the progression of NAFLD and evaluate the potential of novel therapeutic interventions, thereby contributing to the advancement of treatments for this prevalent condition.

Our Gubra-Amylin NASH (GAN) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model

• Available Animal

• C57BL/6 mouse

• Modeling Method

After acclimation, animals are fed GAN diet to induce NAFLD.

• Endpoints

• Body weight
• Liver weight
• Serum analysis: ALT, AST, TG, TC
• Histology analysis: H&E staining, Oil red O staining
• qPCR or Western blot
• Other customized endpoints

Example Data

Fig. 1 Dietary intervention improves metabolic markers in GAN DIO-NASH mice. (A) Body weight profile and terminal body weight. (B) Terminal liver weight. (C) Plasma and liver biochemistry. Plasma ALT; plasma AST; plasma triglycerides; plasma total cholesterol; liver triglycerides; liver total cholesterol. (Flensted-Jensen et al. 2024)

In addition, we also provide other NAFLD models that maybe you are interested in:

• High-fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
• Methionine and Choline Deficient (MCD) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
• Streptozotocin (STZ) & High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model

Quotation and Ordering

Creative Bioarray is widely recognized as a leading non-clinical Contract Research Organization (CRO) at the forefront of preclinical drug development. Our distinguished reputation is built upon our unwavering commitment to providing you with the most rigorously validated and dependable disease models for the meticulous testing of your compounds. If you are interested in our services, please do not hesitate to contact us at any time or submit an inquiry to us directly.

Reference

1. Flensted-Jensen M, Oró D, et al. Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH. BMC gastroenterology, 2024, 24(1): 59.

Explore Other Options

• Alloxan-Induced Type 1 Diabetes Model
• Animal Model of Hyperuricemia
• High Fat Diet-Induced Obesity Model
• Nonalcoholic Fatty Liver Disease Model
• Type 1 Diabetes Mellitus Model

• High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
• Methionine and Choline Deficient (MCD) Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model
• Streptozotocin (STZ) & High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease (NAFLD) Model

For research use only. Not for any other purpose.